Abstract: The translation of biomedical innovation needs to be promoted by the cooperation of academic research institutions, biotechnology companies and large pharmaceutical companies, among which the benefits are distributed through technology and patent licensing, thus generating drug royalties. Royalty investment is a kind of investment mode that has evolved on this basis, enabling research institutions and biopharmaceutical companies to monetise their patents as quickly as possible, thereby creating greater financial flexibility and giving investors the opportunity to participate in the life sciences industry at a lower risk. In this article, Royalty Pharma, the largest drug royalty investment company in the United States, has been taken as an example. By studying its development history, team, portfolio and investment process, as well as combining with the development situation of China's biomedical industry, the feasibility of implementing drug royalty investment in China has been analyzed.